Clinical Trial Update: Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of nivolumab, cabiralizumab, and SBRT for locally advanced unresectable pancreatic cancer was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Cabiralizumab
• Stereotactic Body Radiotherapy
• nivolumab (nivolumab)

Snippet

Sponsor: NYU Langone Health | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-10-19